Most significant clincal trials of 2024 - Yahoo Finance

2024 saw significant clinical trial activity, with Phase I and II trials dominating. Notable successes included Gilead's lenacapavir for HIV PReP, Scholar Rock's apitegromab for SMA, and Lilly's Zepbound for obesity. However, failures like Amylyx's Relyvrio for ALS and Pfizer's DMD gene therapy highlighted challenges. Eisai's Leqembi for Alzheimer's also showed positive results.

Related Clinical Trials

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Open-label Extension for Phase 3 Clinical Trials of Simufilam

Related News

finance.yahoo.com
Most significant clincal trials of 2024 - Yahoo Finance

2024 saw significant clinical trial activity, with Phase I and II trials dominating. Notable successes included Gilead's lenacapavir for HIV PReP, Scholar Rock's apitegromab for SMA, and Lilly's Zepbound for obesity. However, failures like Amylyx's Relyvrio for ALS and Pfizer's DMD gene therapy highlighted challenges. Eisai's Leqembi for Alzheimer's also showed positive results.

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy